MDABY Stock UPDATES Meda Ab (MDABY) 16.0400 08/03/2014 18:07
Post# of 273256
Posted On: 08/03/2014 7:07:44 PM
Meda Ab (MDABY) 16.0400 $MDABY
Fibromyalgia - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjrklg/fibromyalgia) has announced the addition of the "Fibromyalgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Meda AB - Pfizer Inc. - Collegium Pharmaceutical, Inc. - Theravance, Inc. - e-Therapeutics plc - Concert Pharmaceuticals, Inc. - SWITCH Biotech LLC - EirGen Pharma Ltd. - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/vj...bromyalgia
Global Non-melanoma Skin Cancer Market 2014-2018: Market Size and CAGR
M2 - Thu Jun 12, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/slg7cn/global) has announced the addition of the "Global Non-melanoma Skin Cancer Market 2014-2018" report to their offering. The analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments: - Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis - Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy Key Vendors - Elekta AB - F. Hoffmann-la Roche Ltd. - iCAD Inc. - Meda AB - Valeant Pharmaceuticals Inc. - Varian Medical Systems Inc. Commenting on the report, an analyst from the team said: A current trend witnessed in the Global Non-melanoma Skin Cancer market is the use of combination therapies for the treatment of non-melanoma skin cancer. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and destruction of cancerous cells. For instance, radiation therapy may be used in combination with other therapies (chemotherapy and surgery) to treat aggressive or recurrent non-melanoma skin cancer. Patients that are non-reactive may react to combination therapy with 0.5 percent tretinoin cream with 5-FU cream. For more information visit http://www.researchandmarkets.com/research/slg7cn/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mission Pharmacal Begins Exclusive Promotion of Elestrin® (estradiol gel) 0.06% in the US Market
PR Newswire - Thu May 29, 4:28PM CDT
Mission Pharmacal Company has begun exclusive promotion of Elestrin® (estradiol gel) 0.06% in the United States through an agreement with Meda AB. Elestrin is a prescription medicine approved by the Food and Drug Administration (FDA) for use as a topical hormone replacement gel to treat moderate-to-severe hot flashes due to menopause. Using estrogen-alone may increase your chance of getting cancer of the uterus (womb).
Meda AB (publ) Notice of Annual General Meeting 2014
Business Wire - Wed Apr 02, 5:30AM CDT
Notice is hereby given that the Annual General Meeting (AGM) of Meda AB (STO:MEDAA), corporate ID 556427-2812, will be held at 5.00 PM on Wednesday, May 7, 2014 at Meda's headquarters at Pipers vag 2A, Solna, Sweden. Registration starts at 4.00 PM.
MEDA: Nomination Committee's Proposal for Composition of the Board
Business Wire - Fri Mar 28, 4:04AM CDT
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Journalists
Business Wire - Tue Feb 11, 7:48AM CST
Meda AB (STO:MEDAA):
Meda announces organisational changes
M2 - Mon Aug 05, 3:20AM CDT
Specialty pharma company Meda AB (STO:MEDAA.ST) announced today that Jorg-Thomas Dierks, its chief operating officer (COO), will now have expanded responsibilities which will include Meda's US operations.
MEDA posts net profit of SEK400m in H1 2013
M2 - Fri Aug 02, 10:07AM CDT
Speciality pharmaceutical company MEDA AB (STO:MEDAA) today reported interim profit after tax of SEK400m, or SEK1.34 per share, for the period January 2013 to June 2013.
Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis
Meda AB (publ) AGM bulletin
Business Wire - Tue May 07, 12:31PM CDT
Regulatory News:
MEDA: Interim Report, January-March 2013
Business Wire - Tue May 07, 1:31AM CDT
Regulatory News:
Warner Chilcott Announces Changes to Board of Directors
GlobeNewswire - Thu May 02, 3:15PM CDT
Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors has voted unanimously to appoint Paul Herendeen, the Company's Executive Vice President and Chief Financial Officer, to the Company's Board effective as of May 2, 2013. Mr. Herendeen will continue to serve as Executive Vice President and Chief Financial Officer of the Company.
FIN® Branding Group Taps Former Burger King & Nestle Exec To Lead Marketing Efforts
PR Newswire - Tue Apr 30, 12:16PM CDT
Leading electronic cigarette company FIN Branding Group has appointed Joana Martins its vice president of marketing. Martins brings more than 14 years of consumer-focused branding to her new role, including stints at Burger King Brands and Nestle USA. At FIN, Martins will develop and execute marketing and communication strategies to position FIN's industry leadership.
Rhinitis - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:21AM CDT
Research and Markets has announced the addition of the "Rhinitis - Pipeline Review, H1 2013" report to their offering. 'Rhinitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinitis. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rhinitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rhinitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strateg
MEDA AB (publ) NOTICE OF ANNUAL GENERAL MEETING 2013
Business Wire - Wed Apr 03, 7:32AM CDT
Regulatory News:
Fibromyalgia - Pipeline Review, H1 2014
M2 - Wed Jul 30, 3:10AM CDT
Research and Markets (http://www.researchandmarkets.com/research/vjrklg/fibromyalgia) has announced the addition of the "Fibromyalgia - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Fibromyalgia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fibromyalgia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Fibromyalgia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Fibromyalgia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope Companies Mentioned: - Eli Lilly and Company - Merck & Co., Inc. - Dainippon Sumitomo Pharma Co., Ltd. - Meda AB - Pfizer Inc. - Collegium Pharmaceutical, Inc. - Theravance, Inc. - e-Therapeutics plc - Concert Pharmaceuticals, Inc. - SWITCH Biotech LLC - EirGen Pharma Ltd. - Tonix Pharmaceuticals Holding Corp. For more information visit http://www.researchandmarkets.com/research/vj...bromyalgia
Global Non-melanoma Skin Cancer Market 2014-2018: Market Size and CAGR
M2 - Thu Jun 12, 9:19AM CDT
Research and Markets (http://www.researchandmarkets.com/research/slg7cn/global) has announced the addition of the "Global Non-melanoma Skin Cancer Market 2014-2018" report to their offering. The analysts forecast the Global Non-melanoma Skin Cancer market to grow at a CAGR of 27.93 percent over the period 2013-2018. Covered in this Report This report covers the present scenario and the growth prospects of the Global Non-melanoma Skin Cancer market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the following segments: - Chemotherapy, which includes drugs used in the treatment of SCC, BCC, and actinic keratosis - Non-invasive Treatments, which include PDT, radiotherapy, cryotherapy, and laser therapy Key Vendors - Elekta AB - F. Hoffmann-la Roche Ltd. - iCAD Inc. - Meda AB - Valeant Pharmaceuticals Inc. - Varian Medical Systems Inc. Commenting on the report, an analyst from the team said: A current trend witnessed in the Global Non-melanoma Skin Cancer market is the use of combination therapies for the treatment of non-melanoma skin cancer. Cancer cells that are confined locally can be easily treated by surgery or radiation therapy, while cancer cells that have spread to distant sites can be killed by chemotherapy. Therefore, combination therapies help in the complete removal of tumors and destruction of cancerous cells. For instance, radiation therapy may be used in combination with other therapies (chemotherapy and surgery) to treat aggressive or recurrent non-melanoma skin cancer. Patients that are non-reactive may react to combination therapy with 0.5 percent tretinoin cream with 5-FU cream. For more information visit http://www.researchandmarkets.com/research/slg7cn/global About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Mission Pharmacal Begins Exclusive Promotion of Elestrin® (estradiol gel) 0.06% in the US Market
PR Newswire - Thu May 29, 4:28PM CDT
Mission Pharmacal Company has begun exclusive promotion of Elestrin® (estradiol gel) 0.06% in the United States through an agreement with Meda AB. Elestrin is a prescription medicine approved by the Food and Drug Administration (FDA) for use as a topical hormone replacement gel to treat moderate-to-severe hot flashes due to menopause. Using estrogen-alone may increase your chance of getting cancer of the uterus (womb).
Meda AB (publ) Notice of Annual General Meeting 2014
Business Wire - Wed Apr 02, 5:30AM CDT
Notice is hereby given that the Annual General Meeting (AGM) of Meda AB (STO:MEDAA), corporate ID 556427-2812, will be held at 5.00 PM on Wednesday, May 7, 2014 at Meda's headquarters at Pipers vag 2A, Solna, Sweden. Registration starts at 4.00 PM.
MEDA: Nomination Committee's Proposal for Composition of the Board
Business Wire - Fri Mar 28, 4:04AM CDT
Regulatory News:
MEDA: Invitation to Teleconference for Analysts, Investors and Journalists
Business Wire - Tue Feb 11, 7:48AM CST
Meda AB (STO:MEDAA):
Meda announces organisational changes
M2 - Mon Aug 05, 3:20AM CDT
Specialty pharma company Meda AB (STO:MEDAA.ST) announced today that Jorg-Thomas Dierks, its chief operating officer (COO), will now have expanded responsibilities which will include Meda's US operations.
MEDA posts net profit of SEK400m in H1 2013
M2 - Fri Aug 02, 10:07AM CDT
Speciality pharmaceutical company MEDA AB (STO:MEDAA) today reported interim profit after tax of SEK400m, or SEK1.34 per share, for the period January 2013 to June 2013.
Actinic Keratosis - Pipeline Review, H2 2012
M2 - Fri Aug 02, 6:35AM CDT
Research and Markets (http://www.researchandmarkets.com/research/s2gp3d/actinic_keratosis) has announced the addition of the "Actinic Keratosis - Pipeline Review, H2 2012" report to their offering. This research provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for actinic keratosis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for actinic keratosis. The information is built using data and information sourced from proprietary databases, company/university websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Scope - A snapshot of the global therapeutic scenario for actinic keratosis. - A review of the actinic keratosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the actinic keratosis pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for actinic keratosis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding actinic keratosis pipeline depth and focus of Indication therapeutics. Key Topics Covered: List of Tables List of Figures Introduction Report Coverage Actinic Keratosis Overview Therapeutics Development An Overview of Pipeline Products for Actinic Keratosis Companies Involved in Actinic Keratosis Therapeutics Development Actinic Keratosis - Therapeutics Assessment Drug Profiles Featured News & Press Releases Appendix Companies Mentioned: - Almirall, S.A - Birken GmbH - Celtic Pharmaceutical Holdings L.P - Clinuvel Pharmaceuticals Limited - FunZyme BioTechnologies S.A - GliaMed, Inc - Meda AB - MediQuest Therapeutics, Inc - Moberg Derma AB - NexMed, Inc - Quest PharmaTech Inc - Telormedix SA For more information visit http://www.researchandmarkets.com/research/s2..._keratosis
Meda AB (publ) AGM bulletin
Business Wire - Tue May 07, 12:31PM CDT
Regulatory News:
MEDA: Interim Report, January-March 2013
Business Wire - Tue May 07, 1:31AM CDT
Regulatory News:
Warner Chilcott Announces Changes to Board of Directors
GlobeNewswire - Thu May 02, 3:15PM CDT
Warner Chilcott plc (Nasdaq:WCRX) today announced that its Board of Directors has voted unanimously to appoint Paul Herendeen, the Company's Executive Vice President and Chief Financial Officer, to the Company's Board effective as of May 2, 2013. Mr. Herendeen will continue to serve as Executive Vice President and Chief Financial Officer of the Company.
FIN® Branding Group Taps Former Burger King & Nestle Exec To Lead Marketing Efforts
PR Newswire - Tue Apr 30, 12:16PM CDT
Leading electronic cigarette company FIN Branding Group has appointed Joana Martins its vice president of marketing. Martins brings more than 14 years of consumer-focused branding to her new role, including stints at Burger King Brands and Nestle USA. At FIN, Martins will develop and execute marketing and communication strategies to position FIN's industry leadership.
Rhinitis - Pipeline Review, H1 2013
M2 - Mon Apr 15, 5:21AM CDT
Research and Markets has announced the addition of the "Rhinitis - Pipeline Review, H1 2013" report to their offering. 'Rhinitis - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Rhinitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rhinitis. Reasons to buy - Identify and understand important and diverse types of therapeutics under development for Rhinitis. - Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage. - Plan mergers and acquisitions effectively by identifying players of the most promising pipeline. - Devise corrective measures for pipeline projects by understanding Rhinitis pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strateg
MEDA AB (publ) NOTICE OF ANNUAL GENERAL MEETING 2013
Business Wire - Wed Apr 03, 7:32AM CDT
Regulatory News:
(0)
(0)Scroll down for more posts ▼